Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarconeos - Biophytis

Drug Profile

Sarconeos - Biophytis

Alternative Names: 20-hydroxyecdysone - Biophytis; BIO 101; RUVEMBRI

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biophytis
  • Class Cyclopentanes; Ketones; Obesity therapies; Phenanthrenes; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease
  • Phase II Sarcopenia
  • Phase I Duchenne muscular dystrophy
  • Preclinical Obesity

Most Recent Events

  • 11 Jul 2024 US FDA approves IND application for Sarconeos in Obesity
  • 20 Jun 2024 Biophytis and Blanver agree to co-develop sarconeos in Latin America
  • 12 Jun 2024 Biophytis and SEQENS completed transfer to produce Sarconeos
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top